Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mercedes Corina Becerra, Sc.D.

Co-Author

This page shows the publications co-authored by Mercedes Becerra and Carole Mitnick.
Connection Strength

4.064
  1. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013; 8(3):e58664.
    View in: PubMed
    Score: 0.532
  2. Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. Pediatr Infect Dis J. 2013 Feb; 32(2):115-9.
    View in: PubMed
    Score: 0.528
  3. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011 Jan 08; 377(9760):147-52.
    View in: PubMed
    Score: 0.454
  4. Recurrence after treatment for pulmonary multidrug-resistant tuberculosis. Clin Infect Dis. 2010 Sep 15; 51(6):709-11.
    View in: PubMed
    Score: 0.447
  5. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008 Aug 07; 359(6):563-74.
    View in: PubMed
    Score: 0.387
  6. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019 10 24; 367:l5894.
    View in: PubMed
    Score: 0.210
  7. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J. 2016 10; 48(4):1160-1170.
    View in: PubMed
    Score: 0.169
  8. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis. Ann Am Thorac Soc. 2015 May; 12(5):674-9.
    View in: PubMed
    Score: 0.154
  9. Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment. PLoS One. 2014; 9(9):e108035.
    View in: PubMed
    Score: 0.148
  10. Concordance of resistance profiles in households of patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2014 Feb; 58(3):392-5.
    View in: PubMed
    Score: 0.139
  11. Salvage therapy for multidrug-resistant tuberculosis. Clin Microbiol Infect. 2014 May; 20(5):441-6.
    View in: PubMed
    Score: 0.137
  12. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis. 2013 Mar; 56(6):770-6.
    View in: PubMed
    Score: 0.130
  13. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008 Jun 15; 46(12):1844-51.
    View in: PubMed
    Score: 0.096
  14. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics. 2006 Jun; 117(6):2022-9.
    View in: PubMed
    Score: 0.083
  15. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis. 2004 Jan; 8(1):52-8.
    View in: PubMed
    Score: 0.070
  16. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003 Jan 09; 348(2):119-28.
    View in: PubMed
    Score: 0.066
  17. Erratum for Velásquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2017 Mar; 61(3).
    View in: PubMed
    Score: 0.044
  18. Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2016 11; 60(11):6766-6773.
    View in: PubMed
    Score: 0.043
  19. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015 Mar; 3(3):201-9.
    View in: PubMed
    Score: 0.038
  20. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis. 2014 Jul 01; 59(1):9-15.
    View in: PubMed
    Score: 0.036
  21. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; 9(8):e1001300.
    View in: PubMed
    Score: 0.032
  22. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb). 2012 Sep; 92(5):397-403.
    View in: PubMed
    Score: 0.032
  23. Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experience. Bull World Health Organ. 2012 Jan 01; 90(1):63-6.
    View in: PubMed
    Score: 0.030
  24. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis. 2006 Mar; 10(3):290-6.
    View in: PubMed
    Score: 0.020
  25. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001 Jul; 5(7):648-55.
    View in: PubMed
    Score: 0.015
  26. Management of MDR-TB in resource-poor countries. Int J Tuberc Lung Dis. 1999 Aug; 3(8):643-5.
    View in: PubMed
    Score: 0.013
  27. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis. 1998 Nov; 2(11):869-76.
    View in: PubMed
    Score: 0.012
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.